|
|
|
| The influence of high-activity antiviral therapy on pregnancy outcomes and maternal-to-child block effect of HIV-positive pregnant women with coinfection of HBV |
| Qinghai Red Cross Hospital, Xining, Qinghai 81000 |
|
|
|
|
Abstract To explore the influence of high-activity antiviral therapy (HAART) on pregnancy outcomes and maternal-to-child block effect of HIV-positive pregnant women with coinfection of HBV. Methods: 68 HIV-positive pregnant women were included and were divided in group A (32 women with coinfection of HBV) and group B (36 women without coinfection of HBV) from January 2017 to January 2019. HAART, such as tenofovir, lamivudine and lopinavir/ritonavir, were given the women in both groups. The HIV infection-related indicators and liver function, adverse events during pregnancy, and mother-to-child blocking effect of HIV and HBV of women in the two groups before and after HAART were analyzed. Results: After treatment, HIV DNA copy number and CD4+T cell count of women in both groups had improved significantly, but which had no significant differences between the two groups (P＞0.05). The liver function index and HBsAg positive rate of women in group A had decreased significantly. There were no significant differences in the incidences of adverse pregnancy events, such as preterm birth and miscarriage rates of women, and low birth weight of newborns between the two groups (P＞0.05), but the proportion of Apgar score ≤7 points of newborns in group A (31.3%) was significant higher than that (11.1%) of newborns in group B (P＜0.05), the mother-to-child blocking effect of HIV of women in the two groups was similar, which were both over 90%. Conclusion：HAART for women with co-infection of HIV and HBV will not decrease therapeutic effect, but it maybe increase the possibility of mild asphyxia of newborn, so it is should be paid more attention to in clinic.
|
|
|
|
|
|
|
|
|
